Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

By P. Seo. 2010

815 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (2016, methodology): “Rituximab in AAV has been tested in two RCTs (RAVE and RITUXVAS) (63, 64).”
KDIGO Clinical Practice Guideline for Glomerulonephritis (2012, background): “82% with cyclophosphamide), as were rates of serious adverse events.(713) In Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis (RAVE), 197 patients were randomized to treatment with either rituximab (375 mg/m(2) infusions once weekly for 4 weeks) or cyclophosphamid”
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of ANCA-Associated Vasculitis (2021, neutral): “Data regarding the efficacy of combined cyclophosphamide and rituximab therapy for remission induction remain limited (12), and potential toxicity of this combination remains a concern.”
ANCA-associated vasculitis (2020, background): “Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.”
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. (2014, neutral): “Renal-limited ANCA-associated vasculitis 3 (5) 2 (4) 5 (4)”